Hamilton Health Sciences
Hamilton, Ontario, L8S 4L8, Canada
NCT Number: NCT02230280
Most stroke survivors live with other chronic health conditions that can negatively affect their recovery and overall health and well-being. Although stroke care has improved, there are still many challenges to the delivery of community-based stroke care. These challenges include: poor coordination of care across health care providers and settings; limited communication among health care providers; limited use of evidence-based treatment guidelines; difficulties navigating community services and supports; and limited client and family caregiver involvement in making healthcare decisions. The investigators developed a new mobile health (mHealth) application, My Stroke Team (MYST), to address these challenges to improve the overall quality of stroke care at home. This study will expand this work to: 1) explore the feasibility and acceptability of this mobile tool, 2) determine its impact and usability for home care providers, stroke survivors, and their family caregivers, and 3) determine its impact on the costs of use of health services.
Looking for future studies?
Notify Me55 year and older
All sexes
Interventional
Not applicable
Hamilton, Ontario, L8S 4L8, Canada
Research Questions:
Methods:
Due to the complexity of evaluating health services interventions, a mixed methods design will be used to evaluate the multi-component intervention. A pragmatic pre-test post-test single site study design will be used to evaluate the intervention. By pragmatic, the investigators mean the intervention will be implemented under real-world conditions, including reliance on existing staff at the participating site. Assessments will be made at baseline (pre-test) and immediately following the six-month intervention period (post-test). Descriptive qualitative methods will be used to explore the feasibility and acceptability of the intervention.
Outcomes will be assessed at baseline and 6 months. Summary descriptive measures will be reported for all variables.
Expected Outcomes:
It is expected that stroke survivors with multiple chronic conditions, their family caregivers and healthcare providers will find the MYST app acceptable and feasible.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
Time frame: Baseline and the end of the intervention (6 months from baseline)
The Short-Form 12(SF-12) Health Survey will be administered to stroke survivors and caregivers to measure health-related quality of life
Time frame: At the end of the intervention (6 months)
Participants' perspectives on the feasibility of the mobile application will be assessed qualitatively through focus groups (HCPs) and interviews (stroke survivors and family caregivers).
Time frame: Baseline and the end of the intervention (6 months from baseline)
The Stroke Impact Scale (SIS)-16 will be administered to stroke survivors at baseline and 6 months, to assess physical functioning related to stroke
Time frame: Baseline and the end of the intervention (6 months from baseline)
The Centre for Epidemiological Studies Depression Scale (CES-D-10) will be used to assess the prevalence and the severity of depression symptoms.
Time frame: Baseline and the end of the intervention (6months from baseline)
The Modified Caregiver Strain Index(CSI) will be administered to every stroke survivor's family caregiver at baseline and at 6 months to assess change in burden associated with caregiving
Time frame: Baseline and end of intervention (6 months from baseline)
The Generalized Anxiety Disorder Screener-7 (GAD-7) scale will be used to assess changes in the degree of anxiety of stroke survivors at baseline and 6 months from baseline.
Time frame: Baseline and end of the intervention (6 months from baseline)
The Stanford's 6-item Self-Efficacy for Managing Chronic Disease Scale (SE-MCD) will be administered to stroke survivors to assess changes in self efficacy at baseline and end of the study.
Time frame: Baseline and end of the intervention (6 months from baseline)
The Reintegration to Normal Living Index (RNLI) will be administered to stroke survivors to assess degree of community reintegration post-stroke.
Time frame: Baseline and end of intervention (6 months from baseline)
The costs of use of all types of health services from baseline to six months will be determined using the Health and Social Services Utilization Inventory (HSSUI).
Time frame: At three months into the intervention study and upon completion of the study (16 months)
The Collaborative Practice Assessment Tool will be administered to home care providers to assess changes in team functioning.
Time frame: At three months into the intervention study and upon completion of the study (16 months)
The Team Climate Inventory will be administered to home care providers to assess changes in their level of integration.
McMaster University
Other
Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention That Includes a Mobile Health Solution
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05970367
Brain Diseases, Cardiovascular Diseases
Herentals, Belgium
View Trial DetailsNCT04037436
Arthritis, Bone Diseases
Cambridge, Ontario, Canada
View Trial DetailsNCT01770184
Brain Diseases, Cardiovascular Diseases
St Louis, Missouri, United States
View Trial DetailsNCT01457300
Arthritis, Brain Diseases
Oslo, Norway
View Trial Details